Oncol Rep 36: [Related article:] 1702–1708, 2016; DOI:
10.3892/or.2016.4975
Following the publication of this paper, it was
drawn to the Editors' attention by a concerned reader that a pair
of the lanes featured in the western blot gel for Fig. 3B on p.
1705 were strikingly similar, suggesting that the same data may
have been imported into the figure to represent data that were
intended to show the results from differently performed
experiments. In addition, the western data shown in Fig. 6 on p.
1706 for the GRP78 and the p-PERK proteins also appeared to be
strikingly similar, such that the same data may have also been
inserted into this figure to show the results from different
experiments. Finally, certain of the data in this paper were shown
to have appeared in a previous publication that featured some of
the same authors, albeit in different form [Zhang L, Huang D, Wang
Q, Shen D, Wang Y, Chen B, Zhang J and Gai L: MiR-132 inhibits
expression of SIRT1 and induces pro-inflammatory processes of
vascular endothelial inflammation through blockade of the SREBP-1c
metabolic pathway. Cardiovasc Drugs Ther 8: 303–311, 2014].
Owing to the fact that some of the contentious data
in the above article had already been published elsewhere prior to
its submission to Oncology Reports, and because of an
overall lack of confidence in the presented data, the Editor has
decided that this paper should be retracted from the Journal. The
authors were asked for an explanation to account for these
concerns, but the Editorial Office did not receive a reply. The
Editor apologizes to the readership for any inconvenience
caused.
